| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 3.013 | 6.777 | 15.817 | 10.100 | 7.091 | 6.141 | 13.492 | 12.785 | 7.104 | 10.414 |
| Total Income - EUR | 3.013 | 6.777 | 17.098 | 11.568 | 7.091 | 8.312 | 14.907 | 12.786 | 13.424 | 12.562 |
| Total Expenses - EUR | 4.422 | 7.050 | 12.500 | 9.022 | 7.876 | 15.073 | 13.121 | 6.400 | 18.906 | 8.453 |
| Gross Profit/Loss - EUR | -1.409 | -273 | 4.597 | 2.546 | -785 | -6.761 | 1.786 | 6.386 | -5.481 | 4.109 |
| Net Profit/Loss - EUR | -1.499 | -408 | 4.426 | 2.445 | -856 | -6.842 | 1.637 | 6.035 | -5.583 | 3.467 |
| Employees | 1 | 1 | 2 | 2 | 1 | 2 | 1 | 1 | 2 | 1 |
Check the financial reports for the company - Ursvio-Bioproiect S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 3.807 | 1.074 | 6.514 | 7.860 | 7.014 | 1.151 | 1.511 | 7.192 | 3.902 | 4.664 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 227 | 370 | 553 | 215 | 530 | 566 | 673 | 256 | 1.506 | 3.793 |
| Cash | 3.580 | 704 | 5.961 | 7.645 | 6.484 | 585 | 838 | 6.936 | 2.396 | 871 |
| Shareholders Funds | 2.937 | 272 | 4.694 | 7.052 | 6.060 | -897 | 759 | 6.796 | 1.193 | 4.653 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 869 | 802 | 1.820 | 808 | 954 | 2.048 | 752 | 395 | 2.709 | 11 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7111 - 7111" | |||||||||
| CAEN Financial Year |
7111
|
|||||||||
Comments - Ursvio-Bioproiect S.r.l.